Drug intelligence / Profile preview

HL-300

Development stage: Phase 2
Lead developer: Hangzhou Highlightll Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

HL-300 is a topical small-molecule inhibitor of Tyrosine Kinase 2 (TYK2), Janus Kinase 1 (JAK1), and Janus Kinase 2 (JAK2), currently under development by TLL Pharmaceutical (also known as Highlightll Pharmaceutical). Designed for the treatment of various dermatological diseases, HL-300 aims to provide therapeutic benefit by blocking the signaling of pro-inflammatory cytokines mediated through the JAK-STAT pathway. By utilizing a topical route of administration, the drug is intended to deliver localized treatment while potentially minimizing systemic exposure. HL-300 is currently in Phase 1 clinical trials.

Targets

TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on HL-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-300.

Explore the full profile